Harmony Biosciences had its Relative Strength (RS) Rating upgraded from 66 to 73 Thursday — a welcome improvement, but still below the 80 or better score you look for.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the market's biggest winners often have an RS Rating of at least 80 as they launch their biggest price moves. See if Harmony Biosciences can continue to show renewed price strength and hit that benchmark.
Harmony Biosciences is building a consolidation with a 41.61 buy point. See if it can break out in heavy trade.
The company reported 17% earnings growth in its most recent report. Revenue gains came in at 19%. The company is expected to report its latest earnings and sales numbers on or around Aug. 5.
The company earns the No. 4 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
